Chemistry:Naftidrofuryl

From HandWiki
Revision as of 19:09, 2 August 2023 by DanMescoff (talk | contribs) (linkage)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Naftidrofuryl
Naftidrofuryl.svg
Clinical data
Trade namesPraxilene
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
MetabolismHepatic
Elimination half-life1 - 3.5 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC24H33NO3
Molar mass383.532 g·mol−1
3D model (JSmol)
  (verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.

Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]

Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]

Adverse Effects

Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]

See also

References

  1. ↑ Pan Vascular Medicine: Integrated Clinical Management. Springer. 20 December 2013. pp. 1394–. ISBN 978-3-642-56225-9. https://books.google.com/books?id=B8LsCAAAQBAJ&pg=PA1394. 
  2. ↑ Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. pp. 147–. ISBN 978-94-011-4439-1. https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA147. 
  3. ↑ "Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate". Journal of Pharmacological Sciences 110 (4): 445–50. August 2009. doi:10.1254/jphs.09124FP. PMID 19672037. 
  4. ↑ "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". https://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm. 
  5. ↑ "Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology". Neurology 74 (8): 691–6. February 2010. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124. 
  6. ↑ "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. 14 January 2014. http://www.medicinescomplete.com/mc/martindale/current/9256-a.htm. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Naftidrofuryl&oldid=3169393"